Health Canada NHP fees under the cost recovery program are the line item most brand owners forget to budget for, and it can reshape the economics of a small product line. If you sell natural health products in Canada, or plan to, the proposed charges for site licences, product licences, and the right to sell deserve a place in your financial model. Here's the current state of play, and what it means for planning a launch. The rules are still moving, so the smart move is to understand the structure now rather than react to a bill later.
Key Takeaways
- Cost recovery introduces three fee types: product licence (pre-market) fees, site licence fees, and an annual right-to-sell fee per NPN.
- Proposed pre-market evaluation fees range widely by application type, with site licence fees set separately.
- A small-business relief program offers steep discounts for companies under 100 employees or within a defined revenue band.
- The December 2025 launch date was cancelled; the framework is paused, not gone.
- Budget for these fees during formulation, not after your NPN is granted.
What Cost Recovery Actually Covers
Cost recovery is Health Canada's plan to fund its natural health product program partly through industry fees, the way it already does for drugs. For years, NHP oversight ran without user fees. That is what changed under the proposal.
The proposed structure breaks into three parts. First, pre-market evaluation fees apply to new product licence applications and amendments. Second, a site licence fee applies to each facility that manufactures, packages, labels, or imports NHPs. Third, an annual right-to-sell fee applies to each product that holds an NPN.
The practical implication: every stage of a product's life, from application to ongoing sale, carries its own charge. Brand owners who only planned for the one-time application cost would be caught short by the recurring pieces.
The Proposed Numbers, and Why the Range Is So Wide
Under Health Canada's NHP fees and cost recovery proposal, pre-market evaluation charges spanned roughly $1,124 to $58,332 per application. Furthermore, the top of that range applies to complex submissions that require full scientific evidence review, not to a simple monograph-based product.
Site licence fees were proposed at around $4,784 for a new application or amendment, with an additional annual site fee for each qualifying facility. The right-to-sell fee, charged yearly per NPN, is the piece that scales with your catalogue. A brand with forty SKUs feels it very differently from a brand with three.
Here's what that means in practice: your fee exposure depends less on any single number and more on how many products you carry and how much evidence they need. In addition, a large catalogue of monograph-based tinctures behaves very differently from a small line of novel-claim formulas.
Small-Business Relief Changes the Math
Health Canada paired the proposal with a small-business discount, and it is significant. Businesses with fewer than 100 employees, or with annual revenue between $30,000 and $5 million CAD, would qualify.
The relief is tiered. Qualifying businesses would get a 100% discount on pre-market evaluation fees for their first-ever NHP submission, a 50% discount on subsequent product submissions, and a 25% discount on site licensing and the annual right-to-sell fee.
Worth understanding before you proceed: this structure clearly favours new and smaller brands. As a result, the first product is cheap to license, while the ongoing right-to-sell fees still accumulate as your catalogue grows. Model both the launch cost and the steady-state annual cost, because they tell different stories.
Current Status: Paused, Not Cancelled
Here is the part that trips people up. Health Canada confirmed that the fees would not launch on December 1, 2025, and no new implementation date has been set. However, cost recovery remains in the department's plans, tied to the broader modernization of NHP regulations.
So the fees are paused, not gone. Treating the pause as a permanent reprieve is a mistake, because a finalized framework could revive the schedule with limited notice. Instead, build the fee structure into your long-term product economics now.
This is where a manufacturing partner helps. Understanding site licence and NPN obligations early informs which products are worth licensing and which formats keep compliance simple, and it connects directly to the broader Health Canada NHP compliance picture and the site licence requirements behind it.
How to Budget for Health Canada NHP Fees Now
You do not need final numbers to plan well. Start by mapping every product you intend to license, then flag which ones rely on Health Canada monographs versus which need a full evidence review. That single split drives most of your pre-market fee exposure.
Next, estimate your steady-state annual cost by multiplying an assumed right-to-sell fee across your planned NPN count. Then apply the small-business discounts if you qualify. Finally, revisit the model whenever Health Canada publishes an update.
The short version: treat NHP fees as a permanent operating cost, not a one-time hurdle. If you want help pressure-testing which formats and formulas keep both compliance and cost manageable, the right contract manufacturing partner works through exactly these trade-offs with brand owners. You can also reach out directly to talk through a specific product plan.
Published: July 21, 2026